Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin + rituximab versus investigator's choice rituximab-based chemotherapy in relapsed or refractory CD22-positive aggressive non-Hodgkin lymphoma
NL-OMON39239Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin, rituximab, bendamustine and gemcitabine in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Planned start Sep 2011; status: withdrawn.
02
Drugs
inotuzumab ozogamicinrituximabbendamustinegemcitabine
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NL-OMON39239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39239.